Article -> Article Details

Market Overview

The global gene panel market was valued at USD 1,153.2 Million in 2024 and is projected to reach USD 3,775.0 Million by 2033, growing at a CAGR of 14.08% during 2025-2033. This market expansion is driven by advancements in precision medicine, increasing prevalence of genetic disorders, and rising adoption of next-generation sequencing (NGS) technologies. The market is also propelled by demand for personalized cancer therapies, early detection of hereditary diseases, and expanding applications across oncology, pharmacogenomics, and rare disease research.

Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

Gene Panel Market Key Takeaways

• The global gene panel market size was valued at USD 1,153.2 Million in 2024.
• The market is expected to exhibit a CAGR of 14.08% from 2025 to 2033.
• North America dominates the market with over 36.9% share in 2024.
• Key growth drivers include advancements in precision medicine, rising genetic disorder prevalence, and increased utilization of NGS.
• Personalized cancer therapies and early detection needs further accelerate market growth.
• Declining genetic testing costs and supportive regulatory frameworks enhance accessibility.
• The United States is a major market force with significant investments in genomic research and personalized healthcare.

Sample Request Link: https://www.imarcgroup.com/gene-panel-market/requestsample

Market Growth Factors

The international market for gene panels is driven by the developments in personalized medicine, which provide targeted therapeutic strategies to ensure better patient outcomes. The incidence of genetically transmitted diseases, including cancers and genetic disorders, is on the rise globally, thereby leading to an increased need for efficient genetic analysis platforms like gene panels to be used for precise genetic analysis.

Despite this, market growth is hindered in most countries by:

High Cost of Instruments

The increasing awareness and demand for personalized therapy for cancers are encouraging for market growth because gene panels have made it possible to screen for overall cancer risk and develop strategies accordingly. Early identification of hereditary conditions using genetic screening is helpful for preventative care and helps to lower mortality. The ever-growing acceptance of pre-designed and customized gene panels and at-home screening kits is making them easily accessible to people.

Other contributing factors include lowering costs of genetic testing, technological advancements in genomic analysis tools, and growing uses of genomics in cancer, pharmacogenomics, and rare diseases. Government support, favorable regulatory setting, and funding for genomic research simplify the way to market growth. The use of gene panels in clinical testing and research cements their place in improving personalized health care accuracy and efficiency.

Market Segmentation

Products and Services:

• Test Kits: Constituting around 60.5% of the market in 2024, test kits are favored for their ease of use, accuracy, and growing adoption in clinical diagnostics. Their pre-validated, standardized nature streamlines workflows and supports early genetic disorder detection.
• Testing Services: Included as part of the market offering.

Technique:

• Amplicon-based Approach: Leading with approximately 79.2% market share in 2024, this approach is valued for high efficiency, cost-effectiveness, and suitability for targeted sequencing. It simplifies sample preparation while ensuring accuracy.
• Hybridization-based Approach: Also included in the market classification.

Design:

• Predesigned Gene Panel: Holding around 66.5% of the market in 2024, these panels offer efficient, cost-effective, ready-to-use solutions extensively applied in diagnostics and research.
• Customized Gene Panel: Included under design segment.

Application:

• Cancer Risk Assessment: The largest application at about 54.7% market share in 2024, driven by increasing cancer prevalence and demand for early detection.
• Diagnosis of Congenital Diseases: Included.
• Pharmacogenetics: Included.
• Others: Included.

End User:

• Academic and Research Institutes: Leading with around 42.8% market share in 2024, driven by focus on genetic research, biomarker identification, and advanced therapy development.
• Hospital and Diagnostic Laboratories: Included.
• Pharmaceutical and Biotechnology Companies: Included.

Regional Insights

North America dominates the global gene panel market with over 36.9% share in 2024. This leadership is supported by advanced healthcare infrastructure, substantial investments in genomic research, and widespread utilization of next-generation sequencing technologies. The region's strategic focus on precision medicine and rising incidence of chronic disorders, including cancer and cardiovascular diseases, foster market growth. Canada and the United States are key contributors, with the U.S. holding 75.90% of North America's market share in 2024.

Recent Developments & News

• February 2024: Roche Diagnostics unveiled an enhanced hereditary cancer gene panel featuring over 100 genes, improving diagnostic precision.
• April 2024: Twist Bioscience launched a service for designing and ordering customized gene panels efficiently.
• December 2023: Qiagen introduced a gene panel targeting neurological conditions such as Alzheimer’s and Parkinson’s.
• April 2023: Agilent Technologies introduced a next-generation sequencing assay for somatic variant profiling in solid tumors.
• May 2023: Unipath Specialty Laboratory in India launched the HRD Gene Panel powered by SOPHiA GENETICS technology.

Key Players

• Agilent Technologies Inc.
• BGI Genomics Co. Ltd. (BGI Group)
• Eurofins Scientific SE
• F. Hoffmann-La Roche AG
• Genewiz LLC (Azenta Inc.)
• Illumina Inc.
• Integrated DNA Technologies Inc. (Danaher Corporation)
• Novogene Co. Ltd.
• Qiagen N.V.
• Thermo Fisher Scientific Inc.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Request for customization: https://www.imarcgroup.com/request?type=report&id=8105&flag=E

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302